Cargando…
Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients
COVID-19, the illness caused by infection with the novel coronavirus SARS-CoV-2, is a rapidly spreading global pandemic in urgent need of effective treatments. Here we present a comprehensive examination of the host- and virus-targeted functions of the flavonolignan silibinin, a potential drug candi...
Autores principales: | Bosch-Barrera, Joaquim, Martin-Castillo, Begoña, Buxó, Maria, Brunet, Joan, Encinar, José Antonio, Menendez, Javier A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356916/ https://www.ncbi.nlm.nih.gov/pubmed/32517353 http://dx.doi.org/10.3390/jcm9061770 |
Ejemplares similares
-
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2021) -
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells
por: Verdura, Sara, et al.
Publicado: (2022) -
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
por: Verdura, Sara, et al.
Publicado: (2022) -
Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin
por: Bosch-Barrera, Joaquim, et al.
Publicado: (2016) -
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)